Literature DB >> 15021183

Bronchiolitis obliterans: an update.

Andrew Chan1, Roblee Allen.   

Abstract

PURPOSE OF REVIEW: Bronchiolitis obliterans (BO) occurs in both post-lung transplant and nontransplant-related individuals, and is characterized by mainly irreversible airflow obstruction that is often ultimately progressive. RECENT
FINDINGS: While post-lung transplant BO is a major cause of lung allograft dysfunction, and hence is better characterized than nontransplant-related BO, it is likely that many similarities in pathogenesis and treatment apply to both categories.
SUMMARY: Optimal management for BO remains to be established, and the role of retransplantation in this disease requires further consensus. Minimization of risk factors for BO and earlier detection in the form of methacholine challenge testing and HRCT scans of the chest amongst other forms of detection, may help in the stabilization and possible resolution of early BO.

Entities:  

Mesh:

Year:  2004        PMID: 15021183     DOI: 10.1097/00063198-200403000-00008

Source DB:  PubMed          Journal:  Curr Opin Pulm Med        ISSN: 1070-5287            Impact factor:   3.155


  18 in total

1.  Rapamycin prevents bronchiolitis obliterans through increasing infiltration of regulatory B cells in a murine tracheal transplantation model.

Authors:  Yunge Zhao; Jacob R Gillen; Akshaya K Meher; Jordan A Burns; Irving L Kron; Christine L Lau
Journal:  J Thorac Cardiovasc Surg       Date:  2015-09-07       Impact factor: 5.209

Review 2.  Acute lung injury/acute respiratory distress syndrome (ALI/ARDS): the mechanism, present strategies and future perspectives of therapies.

Authors:  Shi-ping Luh; Chi-huei Chiang
Journal:  J Zhejiang Univ Sci B       Date:  2007-01       Impact factor: 3.066

3.  Efficacy of concomitant administration of clarithromycin and acetylcysteine in bronchiolitis obliterans in seventeen sulfur mustard-exposed patients: An open-label study.

Authors:  Mostafa Ghanei; Kamran Abolmaali; Jafar Aslani
Journal:  Curr Ther Res Clin Exp       Date:  2004-11

4.  Prevention of the second stage of epithelial loss is a potential novel treatment for bronchiolitis obliterans.

Authors:  Yunge Zhao; John F Steidle; Gilbert R Upchurch; Irving L Kron; Christine L Lau
Journal:  J Thorac Cardiovasc Surg       Date:  2012-08-28       Impact factor: 5.209

5.  Fitting and interpreting continuous-time latent Markov models for panel data.

Authors:  Jane M Lange; Vladimir N Minin
Journal:  Stat Med       Date:  2013-06-05       Impact factor: 2.373

6.  Maintenance of airway epithelium in acutely rejected orthotopic vascularized mouse lung transplants.

Authors:  Mikio Okazaki; Andrew E Gelman; Jeremy R Tietjens; Aida Ibricevic; Christopher G Kornfeld; Howard J Huang; Steven B Richardson; Jiaming Lai; Joel R Garbow; G Alexander Patterson; Alexander S Krupnick; Steven L Brody; Daniel Kreisel
Journal:  Am J Respir Cell Mol Biol       Date:  2007-08-23       Impact factor: 6.914

7.  NADPH oxidase in bone marrow-derived cells mediates pulmonary ischemia-reperfusion injury.

Authors:  Zequan Yang; Ashish K Sharma; Melissa Marshall; Irving L Kron; Victor E Laubach
Journal:  Am J Respir Cell Mol Biol       Date:  2008-09-11       Impact factor: 6.914

8.  The role of adenosine A2A receptor signaling in bronchiolitis obliterans.

Authors:  Christine L Lau; Yunge Zhao; Irving L Kron; Mark H Stoler; Victor E Laubach; Gorav Ailawadi; Joel Linden
Journal:  Ann Thorac Surg       Date:  2009-10       Impact factor: 4.330

9.  Treatment with placenta-derived mesenchymal stem cells mitigates development of bronchiolitis obliterans in a murine model.

Authors:  Yunge Zhao; Jacob R Gillen; David A Harris; Irving L Kron; Michael P Murphy; Christine L Lau
Journal:  J Thorac Cardiovasc Surg       Date:  2013-11-04       Impact factor: 5.209

Review 10.  Popcorn lung and bronchiolitis obliterans: a critical appraisal.

Authors:  David Galbraith; David Weill
Journal:  Int Arch Occup Environ Health       Date:  2008-06-12       Impact factor: 3.015

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.